✨ Free AI Report
9 Meters Biopharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research 9 Meters Biopharma, Inc.
Company Research

9 Meters Biopharma, Inc.: Business Overview, Financials & Competitive Analysis

9 Meters Biopharma, Inc. scores 2/10 on the AskCyborg Cyborg Score (Challenged). Ceased operations with no active pipeline—investment thesis invalidated. The company has ceased operations, indicating failed commercialization efforts, likely capital constraints, and inability to advance its clinical pipeline. Stock price has declined significantly, reaching penny stock status with delisting concerns.

9 Meters Biopharma was a clinical-stage biopharmaceutical company focused on treatments for rare digestive diseases and gastrointestinal conditions with unmet needs. The company has ceased operations.

2/ 10Challenged

Cyborg Score thesis

Ceased operations with no active pipeline—investment thesis invalidated....

Read the full analyst-debate transcript →
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest 9 Meters Biopharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for 9 Meters Biopharma, Inc.

AskCyborg analysts argue the bull and bear cases for 9 Meters Biopharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
9 Meters Biopharma, Inc. OverviewStrategic ProfileCompetitive LandscapeKey facts
Get Interactive Report Freeor start reading below

9 Meters Biopharma, Inc. Overview

Pro stress-test →

9 Meters Biopharma was a clinical-stage biopharmaceutical company focused on treatments for rare digestive diseases and gastrointestinal conditions with unmet needs. The company has ceased operations.

Strategic Profile

Pro stress-test →

The company previously focused on developing therapies including vurolenatide for short bowel syndrome and GIP antagonist NM-136 for obesity. Its pipeline-focused business model and clinical-stage status made it dependent on successful development milestones and funding.

Competitive Landscape

Pro stress-test →

As a ceased-stage company, 9 Meters no longer competes in the market. Previously, it competed against established GI therapeutics developers and obesity drug manufacturers.

Key facts

Headquarters: Raleigh, US · Employees: N/A · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for 9 Meters Biopharma, Inc..

  • Company ceased operations after struggling with pipeline advancement and funding
  • Stock declined 90% over the prior year period with delisting concerns
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Compare 9 Meters Biopharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account
NEW · MCP server

Ask your AI assistant about 9 Meters Biopharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare 9 Meters Biopharma, Inc. and its top competitor on Cyborg Score”
“What did 9 Meters Biopharma, Inc. do this quarter?”
“Is 9 Meters Biopharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does 9 Meters Biopharma, Inc. do?+
9 Meters Biopharma was a clinical-stage biopharmaceutical company focused on treatments for rare digestive diseases and gastrointestinal conditions with unmet needs. The company has ceased operations.
What is 9 Meters Biopharma, Inc.'s Cyborg Score?+
9 Meters Biopharma, Inc. has a Cyborg Score of 2/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are 9 Meters Biopharma, Inc.'s main competitors?+
The full competitive landscape for 9 Meters Biopharma, Inc. is in the AskCyborg report.
How can I get the full 9 Meters Biopharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the 9 Meters Biopharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track 9 Meters Biopharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.